

1 **Title**

2 Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China,

3 2020

4

5 **Authors:**

6 Kenji Mizumoto, Gerardo Chowell

7 **Affiliations:**

8 Georgia State University, Atlanta, GA, USA (K. Mizumoto, G. Chowell)

9 Kyoto University, Kyoto, Japan (K. Mizumoto)

10

11

12

## 13 **Abstract**

14           Since the first case of Novel Coronavirus (2019-nCov) was identified in December 2019  
15 in Wuhan City, China, the number of cases continues to grow across China and multiple cases  
16 have been exported to other countries. The cumulative number of reported deaths is at 637 as of  
17 February 7, 2020. Here we statistically estimated the time-delay adjusted death risk for Wuhan as  
18 well as for China excluding Wuhan to interpret the current severity of the epidemic in China. We  
19 found that the latest estimates of the death risk in Wuhan could be as high as 20% in the  
20 epicenter of the epidemic whereas we estimate it ~1% in the relatively mildly-affected areas.  
21 Because the elevated death risk estimates are likely associated with a breakdown of the  
22 medical/health system, enhanced public health interventions including social distancing and  
23 movement restrictions should be effectively implemented to bring the epidemic under control.

24

## 25 **Background**

26           Since the first case of Novel Coronavirus (2019-nCov) was identified in December 2019  
27 in Wuhan City in the Hubei Province of China, the number of cases continues to expand across  
28 China, with multiple exported cases reported in over 25 countries. In particular, the cumulative  
29 number of deaths is at 637 as of February 7, 2020, a figure that will soon surpass the number of  
30 people that succumbed to Severe acute respiratory syndrome (SARS) in 2002-2003 (1).

31           In the context of an emerging infectious disease with pandemic potential, it is critical to  
32 assess not only its ability to spread between humans, but also the associated risk of death from

33 the disease. In particular, the type and intensity of public health interventions are often a function  
34 of these epidemiological metrics. Importantly, in the absence of vaccines or antiviral for SARS-  
35 CoV and 2019-nCov, the effective implementation of non-pharmaceutical interventions (social  
36 distancing) and movement restrictions, which are the only alternative strategies available to  
37 mitigate their spread in the population, also pose significant pressure on the global economy (2).

38 As interventions are gradually implemented and calibrated during the course of an  
39 outbreak, early estimates of the case fatality risk (CFR) provide crucial information for policy  
40 makers. Yet, the estimation of epidemiological characteristics including the CFR during the  
41 course of an outbreak tend to be affected by right censoring and ascertainment bias (3-5). The  
42 phenomenon of right censoring is caused by the gap of illness onset to death between vulnerable  
43 population and healthy population, resulting in underestimation, while ascertainment bias is due  
44 to the unreported bulk of cases with mild symptoms or asymptomatic infection, potentially  
45 leading to overestimation.

46 The purpose of this study is to derive estimates of the time-delay adjusted CFR for 2019-  
47 nCov for Wuhan, China as well as for China excluding the city of Wuhan with quantified  
48 uncertainty in order to interpret the current severity of the epidemic in China.

49

## 50 **Method**

### 51 **Data sources**

52 We use two different types of data. First, daily confirmed cases and deaths in China were  
53 extracted from daily reports published by China government, Hubei Province in China and

54 Wuhan City (7-9). These data were categorized by area of Wuhan City, Hubei Province  
55 excluding Wuhan City or China excluding Hubei Province, considering that over 50% of the  
56 deaths are occurring in Hubei Province. In particular, the great majority of the deaths have  
57 occurred in Wuhan City. The diagnosis of 2019-nCov cases relies solely on polymerase chain  
58 reaction (PCR), as rapid diagnostic tests for this novel coronavirus are yet to be developed.

59 Second, fifty epidemiological descriptions of the patients who died of 2019-nCov  
60 infection were obtained from several sources (7-9). After checking for duplication and missing  
61 data, the sample size of delays from onset to death and from hospitalization to death was 39 and  
62 33, respectively. We fitted a gamma distribution, an exponential distribution and a lognormal  
63 distribution to the distributions and selected the best model based on the AIC. (Figure S1-S2,  
64 Table S1-S2).

#### 65 **Case fatality ratio**

66 Crude CFR is defined as the number of cumulative cases divided by the number of cumulative  
67 deaths at a specific point in time. For the estimation of CFR in real time, we employ the delay  
68 from hospitalization to death,  $h_s$ , which is assumed to be given by  $h_s = H(s) - H(s-1)$  for  $s > 0$   
69 where  $H(s)$  follows a gamma distribution with mean 10.1 days and SD 5.4 days, obtained from  
70 the available observed data. Let  $\pi$  be the time-delay adjusted case fatality ratio, the likelihood  
71 function of the estimate  $\pi$  is

$$L(\pi_{a,t_i}; c_{a,t}, \theta) = \prod_{t_i} \binom{\sum_{t=1}^{t_i} c_{a,t}}{D_{a,t_i}} \left( \pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{D_{a,t_i}} \left( 1 - \pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{\sum_{t=1}^{t_i} c_{a,t} - D_{a,t_i}}$$

72 where  $c_{a,t}$  represents the number of new cases with reported day  $t$  in area  $a$ , and  $D_{a,t}$  is the  
 73 number of new deaths with reported day  $t_i$  in area  $a$  (10-11). We assume that the observed  
 74 cumulative death,  $D_t$  is the result of the binomial sampling process with probability  $\pi$ .

75 We estimated model parameters using a Monte Carlo Markov Chain (MCMC) method in  
 76 a Bayesian framework. Posterior distributions of the model parameters were estimated by  
 77 sampling from the three Markov chains. For each chain, we drew 100,000 samples from the  
 78 posterior distribution after a burn-in of 20,000 iterations. Convergence of MCMC chains were  
 79 evaluated using the potential scale reduction statistic (12-13). Estimates and 95% credibility  
 80 intervals for these estimates are based on the posterior probability distribution of each parameter  
 81 and based on the samples drawn from the posterior distributions.

82 All statistical analyses were conducted in R version 3.6.1 (R Foundation for Statistical  
 83 Computing, Vienna, Austria) using the ‘rstan’ package.

84

## 85 **Results**

86 As of February 5th, 2020, a total of 28001 cases and 563 deaths of 2019-nCov have been  
 87 reported in China. Of the 28001 cases reported in China, 11618 cases (37.3%) are from Wuhan  
 88 City, 10494 cases (33.7%) are from Hubei Province excluding Wuhan City and 8976 cases

89 (28.9%) are from China excluding Hubei Province. Of the 642 deaths in China, 478 deaths  
90 (74.5%) are from Wuhan city, 140 deaths (21.9%) are from Hubei Province and only 24 deaths  
91 (4%) are from China excluding Hubei Province.

92 Figure 1 illustrates the cumulative cases in (A) Wuhan City, (B) Hubei Province  
93 excluding Wuhan City and (C) China excluding Hubei Province, and the cumulative deaths in  
94 (D) Wuhan City, (E) Hubei Province excluding Wuhan City and (F) Mainland China excluding  
95 Hubei Province, respectively. The curve of the cumulative number of deaths grows after that of  
96 the cumulative number of cases, and the increase in the number of deaths in Wuhan City is  
97 occurring more rapidly and the associated mortality burden appears to be much higher relative to  
98 rest of China, while the cumulative case counts for the three areas in China are similar.

99 Figure 2 displays the observed and model-based posterior estimates of crude CFR in (A)  
100 Wuhan City, (B) Hubei Province excluding Wuhan City and (C) Main land China excluding  
101 Hubei Province, and model-based posterior estimates of time-delay adjusted CFR in (D) Wuhan  
102 City, (E) Hubei Province excluding Wuhan City and (F) Mainland China excluding Hubei  
103 Province, January – February in 2020, respectively. Our model-based crude CFR fitted the  
104 observed data well throughout the course of the epidemic except for the very early stage. During  
105 the course of the outbreak, our model-based posterior estimates of time-delay adjusted CFR take  
106 much higher values than the observed crude CFR, excluding at the early stage in Wuhan City  
107 and the later stage in China excluding Hubei Province. Our estimates of the time-delay adjusted  
108 CFR appear to be decreasing almost consistently in Hubei Province excluding Wuhan City and  
109 in China excluding Hubei Province, whereas in Wuhan city, estimates were low at the early stage  
110 and then increased and peaked in the midst of the study period, and are now following a  
111 decreasing trend similar to the other two areas, reaching estimates around 20%.

112           The latest estimates of the time-delay adjusted CFR are at 18.9% (95%CrI: 17,1-20.8%)  
113   in Wuhan City, 6.1% (95%CrI: 5.2-7.1%) in Hubei Province excluding Wuhan City and 0.9%  
114   (95%CrI: 0.6-1.3%) in China excluding Hubei Province, while the observed crude CFR takes  
115   4.1% (95% Confidence Interval: 3.8%-4.5%) in Wuhan City, 1.3% (95%CI: 1.1-1.6%) in Hubei  
116   Province excluding Wuhan City and 0.27 % (95%CI: 0.2-0.4%) in China excluding Hubei  
117   Province, respectively. (Figure 3, Table)

118

## 119   **Discussion**

120           In this paper we have derived estimates of the CFR for the ongoing 2019-nCov outbreak  
121   in China. We have estimated time-delay adjusted CFR in three different areas in China and found  
122   that the most severely affected areas are Wuhan City as well as the Hubei Province excluding  
123   Wuhan City while the rest of China exhibits a milder impact (China excluding Hubei Province).

124           We found that the latest estimates of the delay adjusted CFR in Wuhan City is as high as  
125   18.9% (95%CrI: 17.1-20.8%), an estimate that his 3-fold higher than our estimate for Hubei  
126   Province excluding Wuhan City and around 20-fold higher than our estimate for China excluding  
127   Hubei Province. These findings suggest that the ongoing situation in Wuhan is particularly dire  
128   compared to the other affected areas. Upward trend of CFR at the early phase generally indicates  
129   a deterioration of an ascertainment bias.

130           However, this upward trend should be interpreted with caution. In particular, the  
131   difficulties in diagnosis cases of 2019-Cov because the associated symptoms are not specific.  
132   Further, the fraction of 2019-Cov patients who develop mild symptoms including asymptomatic  
133   patients is not minor, which complicates detection and diagnosis early after symptoms onset,

134 leading to ascertainment bias (14-15). Indeed, out of a total of 566 Japanese returnees who  
135 evacuated Wuhan city by government-chartered plane during January 29-31 in 2020, a total of 5  
136 asymptomatic and 4 symptomatic 2019-nCov cases were detected after detailed medical  
137 examination (16). However, considering that this underestimation occurred during the course of  
138 outbreak and the number of deaths is relatively accurately reported, the upward trend indicates  
139 that the temporal disease burden exceeded the capacity of medical facilities and the surveillance  
140 system likely missed many cases during the early phase. Additionally, hospital-based  
141 transmission is likely occurring, affecting healthcare workers, inpatients and visitors to medical  
142 facilities, which could explain an increase trend and elevated CFR estimates. Indeed, nosocomial  
143 outbreaks of MERS and SARS nosocomial outbreaks have been reported (17-18). Inpatients with  
144 underlying disease or seniors infected in the hospital setting have raised the CFR to values as  
145 high as 20% for MERS (19-20). More generally, 2019-nCov transmission is facilitated in  
146 confined settings. For instance, a large cluster of 2019-Cov secondary infection has been  
147 reported aboard a cruise ship, with 61 confirmed cases representing about a fifth of the people  
148 tested for the virus, supporting high transmissibility of 2019-nCov in confined conditions (21).

149         A downward trend in CFR is suggestive of the extent of improvements in  
150 epidemiological surveillance. In addition, this pattern indirectly supports a significant number of  
151 mild or asymptomatic cases in Wuhan City, and the underlying transmission might prolong the  
152 end of the outbreak or further transmission to other areas unless effective social distancing  
153 measures are implemented while a vaccine becomes available. Furthermore, given that both the  
154 delay adjusted CFR and crude CFR estimates in Wuhan City are around 20-fold higher than our  
155 estimates for China excluding Hubei Province suggests a breakdown in medical care delivery  
156 and points to the critical need for urgent medical support in the epicenter of the epidemic.



157 We also found that the estimates of delay adjusted CFR both in in Hubei Province  
158 excluding Wuhan City and in China excluding Hubei Province show a time-dependent declining  
159 trend as the epidemic progresses. Indeed, a similar trend has been previously reported for the  
160 Middle East Respiratory Syndrome (MERS) outbreak in the Republic of Korea in 2015, where a  
161 significant fraction of the cases had comorbidities or were senior patients (16-17). If the  
162 proportion of vulnerable cases is high at the early phase and gets proportionally smaller in the  
163 later stage of the outbreak, this partly explains the time dependent decline. However, since the  
164 epidemic has yet to peak, this time dependent decrease is likely caused by ascertainment bias.  
165 Moreover, both of the latest estimates of the delay adjusted CFR and crude CFR in Hubei  
166 Province are around 6-7 fold higher than that in China excluding Hubei Province, where the  
167 health care system has not reached peak capacity. This also indicates the need to anticipate for  
168 additional medical support to deliver medical care to the most vulnerable and at highest risk of  
169 succumbing to the disease from underlying medical conditions.

170 Our study is not free from limitations. First, our CFR estimate is influenced by  
171 ascertainment bias and this might influence estimates upwards. For those infectious diseases  
172 characterized by a large fraction cases with mild or asymptomatic illness, the infection fatality  
173 risk, e.g., the number of death divided by the total infected, is a more appropriate index of  
174 disease burden (22-23). For this purpose, mass serological surveillance and surveys to assess the  
175 presence/absence of symptoms is strongly recommended to disentangle the threat of emerging  
176 infectious diseases including 2019-nCov.

177 Second, in our estimation we employed the time delay distribution from illness onset to  
178 deaths (N=39), which was obtained from secondary sources, but the available data does not

179 include either the date of illness onset or the confirmed date. For this reason, we utilized the time  
180 delay from hospitalization to death (N=33).

181 In conclusion, our latest estimates of the risk of 2019-Cov deaths in China could be as  
182 high as 20% in the epicenter of the epidemic whereas this estimate is around 1% in the relatively  
183 mildly-affected areas in China as of February 5<sup>th</sup>, 2020. Because it is likely that the death risk  
184 from 2019-nCov is associated with a breakdown of the medical/health system in the absence of  
185 pharmaceutical interventions (vaccination and antiviral drugs), enhanced public health  
186 interventions including social distancing, quarantine, enhanced infection control in healthcare  
187 settings and movement restrictions should be effectively implemented to rapidly contain this  
188 epidemic.

189

## 190 **Acknowledgments**

191 KM acknowledges support from the Japan Society for the Promotion of Science (JSPS)  
192 KAKENHI Grant Number 15K20936, from Program for Advancing Strategic International  
193 Networks to Accelerate the Circulation of Talented Researchers Grant Number G2801 and from  
194 the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture,  
195 Sport, Science & Technology of Japan.  
196 GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA  
197 Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological  
198 Sciences Research Council grant BB/M008894/1.

199

200

## 201 **References**

- 202 1. World Health Organization. Summary of probable SARS cases with onset of illness from  
203 1 November 2002 to 31 July 2003 [cited 2020 Feb 7].  
204 [https://www.who.int/csr/sars/country/table2004\\_04\\_21/en/](https://www.who.int/csr/sars/country/table2004_04_21/en/)

- 205 2. Castillo-Garsow MA, Castillo-Chavez C. *J Theor Biol.* 2003;224(1):1-8. SARS outbreaks  
206 in Ontario, Hong Kong and Singapore: the role of diagnosis and isolation as a control  
207 mechanism. Chowell G, Fenimore PW,
- 208 3. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, et al. Methods for  
209 estimating the case fatality ratio for a novel, emerging infectious disease. *Am J*  
210 *Epidemiol.* 2005; 162: 479-486
- 211 4. Kucharski AJ, Edmunds WJ, Case fatality rate for Ebola virus disease in west  
212 Africa. *Lancet.* 2014; 384: 1260
- 213 5. Jewell NP, Lei X, Ghani AC, Donnelly CA, Leung GM, Ho LM et al. Non-parametric  
214 estimation of the case fatality ratio with competing risks data: an application to Severe  
215 Acute Respiratory Syndrome (SARS). *Stat Med.*;26(9):1982-1998.
- 216 6. Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, et al. Assessing the  
217 severity of the novel influenza A/H1N1 pandemic. *BMJ.* 2009; 339: b2840
- 218 7. The State Council, The People's Republic of China. [cited 2020 Feb 7].  
219 <http://www.gov.cn/>
- 220 8. Health Commission of Hubei Province, China. [cited 2020 Feb 7].  
221 <http://wjw.hubei.gov.cn/>
- 222 9. Health Commission of Wuhan City, Hubei Province, China [cited 2020 Feb 7]  
223 <http://wjw.hubei.gov.cn/>
- 224 10. Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JA. Early epidemiological  
225 assessment of the virulence of emerging infectious diseases: a case study of an influenza  
226 pandemic. *PLoS One.* 2009;4(8):e6852. doi: 10.1371/journal.pone.0006852.

- 227 11. Tsuzuki S, Lee H, Miura F, Chan YH, Jung SM, Akhmetzhanov AR, Nishiura H.  
228 Dynamics of the pneumonic plague epidemic in Madagascar, August to October  
229 2017. *Euro Surveill.* 2017;22(46). doi: 10.2807/1560-7917.ES.2017.22.46.17-00710.
- 230 12. Gamerman, D. & Lopes, H. F. *Markov Chain Monte Carlo: Stochastic Simulation for*  
231 *Bayesian Inference.* 2nd edn (Chapman & Hall/CRC, 2006).
- 232 13. Gelman, A. & Rubin, D. B. Inference from iterative simulation using multiple sequences.  
233 *Stat Sci* 7, 457-472, doi:10.1214/ss/1177011136 (1992).
- 234 14. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an  
235 Asymptomatic Contact in Germany. *N Engl J Med.* 2020. doi: 10.1056/NEJMc2001468.
- 236 15. Kai Kupferschmidt. Study claiming new coronavirus can be transmitted by people  
237 without symptoms was flawed. Feb.3,2020, 5:30 PM Available from:  
238 [https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-](https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong)  
239 [coronavirus-wrong](https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong) [Accessed February 4, 2020]
- 240 16. Ministry of Health, Labour and Welfare, Japan. Available from  
241 <https://www.mhlw.go.jp/index.html> [in Japanese]
- 242 17. Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, Viboud C. Transmission  
243 characteristics of MERS and SARS in the healthcare setting: a comparative study. *BMC*  
244 *Med.* 2015;13:210. doi: 10.1186/s12916-015-0450-0.
- 245 18. Abdirizak F, Lewis R, Chowell G. Evaluating the potential impact of targeted vaccination  
246 strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and  
247 Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare  
248 setting. *Theor Biol Med Model.* 2019 ;16(1):16. doi: 10.1186/s12976-019-0112-6.

- 249 19. Mizumoto K, Endo A, Chowell G, Miyamatsu Y, Saitoh M, Nishiura H. Real-time  
250 characterization of risks of death associated with the Middle East respiratory syndrome  
251 (MERS) in the Republic of Korea, 2015. *BMC Med.* 2015;13:228. doi: 10.1186/s12916-  
252 015-0468-3.
- 253 20. Mizumoto K, Saitoh M, Chowell G, Miyamatsu Y, Nishiura H. Estimating the risk of  
254 Middle East respiratory syndrome (MERS) death during the course of the outbreak in the  
255 Republic of Korea, 2015. *Int J Infect Dis.* 2015;39:7-9. doi: 10.1016/j.ijid.2015.08.005.
- 256 21. Gale A, Bhattacharya S. Japan Reports 41 New Coronavirus Infections on Quarantined  
257 Cruise Liner. *The wall street Journal.* Feb. 7, 2020. [https://www.wsj.com/articles/japan-](https://www.wsj.com/articles/japan-reports-41-new-coronavirus-infections-on-quarantined-cruise-liner-11581045439)  
258 [reports-41-new-coronavirus-infections-on-quarantined-cruise-liner-11581045439](https://www.wsj.com/articles/japan-reports-41-new-coronavirus-infections-on-quarantined-cruise-liner-11581045439)
- 259 22. J.Y. Wong, P. Wu, H. Nishiura, E. Goldstein, E.H. Lau, L. Yang, et al. Infection fatality  
260 risk of the pandemic A(H1N1)2009 virus in Hong Kong *Am J Epidemiol.*, 177 (8)  
261 (2013), pp. 834-840
- 262 23. Presanis AM, De Angelis D; New York City Swine Flu Investigation Team, Hagy A,  
263 Reed C, Riley S, Cooper BS, et al. The severity of pandemic H1N1 influenza in the  
264 United States, from April to July 2009: a Bayesian analysis. *PLoS Med.*  
265 2009;6(12):e1000207.

266

267

268 Address for correspondence: Kenji Mizumoto, Graduate School of Advanced Integrated  
269 Studies in Human Survivability, Kyoto University, Yoshida-Nakaadachi-cho, Sakyo-ku,  
270 Kyoto 606-8306, Japan; email: [mizumoto.kenji.5a@kyoto-u.ac.jp](mailto:mizumoto.kenji.5a@kyoto-u.ac.jp)

271

272 Table. Summary results of time-delay adjusted case fatality ratio of 2019-nCov in the 3 areas in China,  
273 2020 (As of February 6, 2020)

Area	Latest estimate	Range of median estimates during the study period	Crude CFR
Wuhan City	18.9% (95%CrI <sup>§</sup> : 17.1-20.8%)	4.1%-34.7%	4.1% (95%CI <sup>†</sup> : 3.8-4.5%) 478/11618
Hubei Province excluding Wuhan City	6.1% (95%CrI: 5.2-7.1%)	6.1%-88.5%	1.3 % (95%CI: 1.1-1.6%) 140/10494
Mainland China excluding Hubei Province	0.9% (95%CrI: 0.6-1.3)	0.67%-55.9%	0.27% (95%CI: 0.2-0.4%) 24/8976

274 <sup>§</sup>CrI: 95% credibility intervals (CrI), <sup>†</sup>95%CI: 95% confidence interval

275

276

277 **Fig 1: Temporal distribution of cases and deaths by area due to 2019-nCov, China, January –**  
278 **February 2020.**

279 Cumulative cases in (A) Wuhan City, (B) Hubei Province excluding Wuhan City and (C) Main land China  
280 excluding Hubei Province, and cumulative deaths in (D) Wuhan City, (E) Hubei Province excluding  
281 Wuhan City and (F) Main land China excluding Hubei Province, over time. Day 1 corresponds to January  
282 1<sup>st</sup> in 2020. As the dates of illness onset were not available, we used dates of reporting.

283

284 **Fig 2: Temporal variation of risk of death caused by 2019-nCov, China, January – February 2020.**

285 Observed and posterior estimated of crude case fatality ratio in (A) Wuhan City, (B) Hubei Province  
286 excluding Wuhan City and (C) Main land China excluding Hubei Province, and time-delay adjusted case  
287 fatality ratio in (D) Wuhan City, (E) Hubei Province excluding Wuhan City and (F) Main land China  
288 excluding Hubei Province. Day 1 corresponds to January 1<sup>st</sup> in 2020. Black dots shows crude case fatality  
289 ratio, and light and dark indicates 95% and 50% credible intervals for posterior estimates, respectively.

290

291 **Figure 3. Latest estimates of time-delay adjusted risk of death caused by 2019-nCov by area, 2020,**  
292 **China.**

293 Distribution of time-delay adjusted case fatality risks derived from the latest estimates (February 6, 2020)  
294 are presented. Top: Wuhan City, Middle: Hubei Province excluding Wuhan City, Bottom: Mainland China  
295 excluding Hubei Province.

296

297 **Appendix Table S1. Summary of delay distribution from hospitalization to death, 2020, China.**

298 Gamma, exponential and exponential distribution were fitted to the available observed data, and  
299 estimated parameters and AIC for each distribution are presented (N=33).

300

301 **Appendix Table S2. Summary of delay distribution from illness onset to death, 2020, China.**

302 Gamma, exponential and exponential distribution were fitted to the available observed data, and  
303 estimated parameters and AIC for each distribution are presented (N=39).

304

305 **Appendix Figure S1. Delay distribution from hospitalization to death, 2020, China.**







306 Gamma (dark, dashed), exponential distribution (light black, dashed) and kernel density distribution  
307 (black, full) were fitted to the available observed data (N=33).

308 **Appendix Figure S2. Delay distribution from illness onset to death, 2020, China.**


309 Gamma (dark, dashed), exponential distribution (light black, dashed) and kernel density distribution  
310 (black, full) were fitted to the available observed data (N=39).

311







Crude case fatality ratio  
Observed and Estimated  
Wuhan




Crude case fatality ratio  
Observed and Estimated  
Hubei(-Wuhan)




Crude case fatality ratio  
Observed and Estimated  
China(-Hubei)




Time adjusted case fatality ratio  
Crude and time adjusted  
Wuhan



Time adjusted case fatality ratio  
Crude and time adjusted  
Hubei(-Wuhan)



Time adjusted case fatality ratio  
Crude and time adjusted  
China(-Hubei)



Time delay adjusted CFR by area  
The latest estimate

